Scarica l'app Stockscreener
12.77
0.39%
-0.05
Dopo l'orario di chiusura:
12.95
0.18
+1.41%
Precedente Chiudi:
$12.82
Aprire:
$12.82
Volume 24 ore:
473.51K
Relative Volume:
0.80
Capitalizzazione di mercato:
$645.07M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-2.4278
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
-2.00%
1M Prestazione:
+32.33%
6M Prestazione:
+32.88%
1 anno Prestazione:
+48.66%
Intervallo 1D:
$12.61
$13.20
Intervallo di 1 settimana:
$12.61
$13.93
Portata 52W:
$5.035
$13.93
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta RGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
12.77 | 647.59M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
Visualizing REGENXBIO Inc. stock with heatmapsJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Analyzing recovery setups for REGENXBIO Inc. investorsMarket Performance Recap & Safe Entry Momentum Tips - newser.com
Can REGENXBIO Inc. (RB0) stock deliver strong annual returnsWeekly Trade Summary & Growth-Oriented Investment Plans - newser.com
Why REGENXBIO Inc. stock appeals to dividend seekersPortfolio Value Summary & Long-Term Growth Plans - newser.com
Is REGENXBIO Inc. stock overvalued by current metricsCEO Change & Weekly Watchlist for Hot Stocks - newser.com
Using economic indicators to assess REGENXBIO Inc. potentialWeekly Profit Report & Free Weekly Chart Analysis and Trade Guides - newser.com
AlphaQuest LLC Cuts Position in REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulusPortfolio Update Report & Verified Momentum Stock Alerts - newser.com
Historical volatility pattern of REGENXBIO Inc. visualizedWeekly Trend Recap & Verified Short-Term Plans - newser.com
Is now a turning point for REGENXBIO Inc.Fed Meeting & Reliable Price Action Trade Plans - newser.com
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why REGENXBIO Inc. stock is considered a top pickBreakout Watch & Technical Entry and Exit Tips - newser.com
Reversal indicators forming on REGENXBIO Inc. stockJuly 2025 Movers & AI Based Buy and Sell Signals - newser.com
RegenXBio (RGNX) Receives a Buy from H.C. Wainwright - The Globe and Mail
Is REGENXBIO Inc. stock undervalued vs historical averagesJuly 2025 Sentiment & Fast Moving Stock Watchlists - newser.com
Will REGENXBIO Inc. (RB0) stock outperform Dow Jones2025 EndofYear Setup & Precise Swing Trade Alerts - newser.com
Price momentum metrics for REGENXBIO Inc. explainedJuly 2025 Action & Daily Growth Stock Investment Tips - newser.com
Will REGENXBIO Inc. (RB0) stock sustain uptrend momentumInsider Selling & Technical Pattern Based Buy Signals - newser.com
What data driven models say about REGENXBIO Inc.’s futurePortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Using Ichimoku Cloud for REGENXBIO Inc. technicals2025 Momentum Check & High Accuracy Swing Trade Signals - newser.com
REGENXBIO concludes subject enrolment in trial of RGX-202 - Clinical Trials Arena
Will REGENXBIO Inc. stock see PE expansionJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Will REGENXBIO Inc. stock go up soonWeekly Investment Recap & Step-by-Step Swing Trade Plans - newser.com
REGENXBIO Inc. stock daily chart insightsBond Market & Capital Protection Trading Alerts - newser.com
Should I buy REGENXBIO Inc. (RB0) stock before earnings seasonRecession Risk & Verified High Yield Trade Plans - newser.com
Regenxbio (RGNX) Completes Enrollment for Duchenne Gene Therapy Trial - GuruFocus
REGENXBIO Inc. Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program - MarketScreener
REGENXBIO completes pivotal trial enrollment for Duchenne gene therapy - Investing.com
Regenxbio announces completion of pivotal enrollment and initiates commercial production in Duchenne gene therapy program - MarketScreener
REGENXBIO completes pivotal trial enrollment for Duchenne gene therapy By Investing.com - Investing.com Nigeria
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program - The AI Journal
REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program - TradingView
REGENXBIO (NASDAQ: RGNX) completes RGX-202 enrollment of 30, starts commercial supply - Stock Titan
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):